S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
S&P 500   4,203.26 (-0.05%)
DOW   32,910.68 (-0.55%)
QQQ   351.61 (+0.92%)
AAPL   177.50 (+1.18%)
MSFT   333.09 (+0.06%)
META   265.40 (+1.28%)
GOOGL   124.41 (-0.16%)
AMZN   121.89 (+1.48%)
TSLA   200.87 (+3.99%)
NVDA   410.63 (+5.44%)
NIO   7.53 (-2.21%)
BABA   78.65 (-2.87%)
AMD   127.25 (+0.17%)
T   15.62 (+0.77%)
F   12.68 (+4.88%)
MU   73.27 (-0.89%)
CGC   0.86 (-1.55%)
GE   101.82 (-0.90%)
DIS   87.61 (-0.77%)
AMC   4.57 (-1.51%)
PFE   37.11 (-1.30%)
PYPL   59.60 (-1.03%)
NFLX   396.01 (+4.52%)
NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Forecast, Price & News

$27.00
-0.37 (-1.35%)
(As of 10:41 AM ET)
Compare
Today's Range
$26.96
$27.57
50-Day Range
$25.16
$28.86
52-Week Range
$20.12
$32.51
Volume
7,244 shs
Average Volume
76,432 shs
Market Capitalization
$398.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7.8% Upside
$29.50 Price Target
Short Interest
Bearish
3.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.83
Upright™ Environmental Score
News Sentiment
1.08mentions of Anika Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.13) to ($0.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

934th out of 1,009 stocks

Surgical & Medical Instruments Industry

94th out of 104 stocks


ANIK stock logo

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

New "Mined in America" Lithium Opportunities?
The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.
Hemostatic Agents Market Research | 2023-2030
ANIK Anika Therapeutics, Inc.
Is Graphite the New Lithium?
Did you know that graphite (NOT lithium) is the largest component of lithium batteries used for EV's? Unfortunately, there are no graphite-producing mines in North America today. This leaves the U.S. at the mercy of China for our vital graphite supply.
Barrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)
Cross-linked Hyaluronic Acid Market Demand by 2031
8-K: Anika Therapeutics, Inc.
Biomaterials Market Overview and Scope By 2030
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Company Calendar

Last Earnings
3/06/2023
Today
5/29/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
297
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$29.50
High Stock Price Forecast
$31.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+7.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-14,860,000.00
Pretax Margin
-17.18%

Debt

Sales & Book Value

Annual Sales
$156.24 million
Cash Flow
$0.51 per share
Book Value
$19.55 per share

Miscellaneous

Free Float
14,310,000
Market Cap
$403.98 million
Optionable
Optionable
Beta
0.83

Social Links


Key Executives

  • Cheryl Renee Blanchard
    President, Chief Executive Officer & Director
  • Anne Nunes
    Vice President-Operations
  • Michael L. LevitzMichael L. Levitz
    Chief Financial Officer, Treasurer & EVP
  • Mira Leiwant
    VP-Quality, Regulatory & Clinical Affairs
  • Steven W. Ek
    Vice President-Research & Development













ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price forecast for 2023?

2 brokers have issued 12-month price objectives for Anika Therapeutics' stock. Their ANIK share price forecasts range from $28.00 to $31.00. On average, they anticipate the company's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK stock has decreased by 7.5% and is now trading at $27.37.
View the best growth stocks for 2023 here
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Monday, March, 6th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biotechnology company had revenue of $39.62 million for the quarter, compared to analysts' expectations of $38.32 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 3.77% and a negative net margin of 14.15%.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $161.06 million.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.67%), Trigran Investments Inc. (10.85%), Dimensional Fund Advisors LP (6.64%), State Street Corp (6.23%), Caligan Partners LP (4.85%) and Renaissance Technologies LLC (3.90%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $27.37.

How much money does Anika Therapeutics make?

Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $403.98 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does Anika Therapeutics have?

The company employs 297 workers across the globe.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -